Altimmune ALT Total Liabilities & Equity
Total Liabilities & Equity at other companies
Other financials
Where this comes from
Reported directly by Altimmune in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.
The official record: Altimmune’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Altimmune's total liabilities & equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Altimmune's total liabilities & equity?
- Altimmune (ALT) reported total liabilities & equity of $335.63M in Q1 2026.
- How has Altimmune's total liabilities & equity changed year-over-year?
- Altimmune's total liabilities & equity increased by 113.4% year-over-year, from $157.26M to $335.63M.
- What is the long-term trend for Altimmune's total liabilities & equity?
- Over 5 years (2020 to 2025), Altimmune's total liabilities & equity has grown at a 2.7% compound annual growth rate (CAGR), from $245.12M to $279.93M.
- What does total liabilities & equity mean?
- Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.